|
CA2405728A1
(en)
*
|
2000-07-31 |
2002-02-07 |
Dabur Research Foundation |
Lipid-peptide conjugates for treatment of cancer
|
|
US6828304B1
(en)
|
2000-07-31 |
2004-12-07 |
Dabur Research Foundation |
Peptides for treatment of cancer
|
|
AU2002236765A1
(en)
|
2001-01-16 |
2002-07-30 |
Glaxo Group Limited |
Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
|
|
KR101476067B1
(ko)
|
2002-09-06 |
2014-12-23 |
인설트 테라페틱스, 인코퍼레이티드 |
공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
|
|
WO2004062684A2
(en)
|
2003-01-16 |
2004-07-29 |
D. Collen Research Foundation Vzw Onderwijs En Navorsing Campus Gasthuisberg K.U. Leuven |
Treatment of thrombocytopenia with inhibitors of pacap
|
|
US7422741B2
(en)
|
2004-03-05 |
2008-09-09 |
Vegenics Limited |
VEGFR-3 fusion proteins
|
|
CZ2004964A3
(cs)
*
|
2004-09-14 |
2006-03-15 |
Pliva-Lachema A. S. |
Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
|
|
JPWO2007094495A1
(ja)
|
2006-02-17 |
2009-07-09 |
国立大学法人九州大学 |
新規な抗がんカテプシン製剤およびそれを用いたがん併用療法抗がん剤
|
|
JP2010516625A
(ja)
|
2007-01-24 |
2010-05-20 |
インサート セラピューティクス， インコーポレイテッド |
制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
|
|
MX366955B
(es)
*
|
2009-09-15 |
2019-07-31 |
Bluelink Pharmaceuticals Inc |
Crlx101 para usarse en el tratamiento de cáncer.
|
|
EP2547359B1
(en)
|
2010-03-15 |
2016-03-09 |
The Board of Trustees of the University of Illionis |
Inhibitors of beta integrin-g protein alpha subunit binding interactions
|
|
EP2655401B1
(en)
|
2010-12-20 |
2016-03-09 |
The Regents of the University of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
|
WO2012161755A2
(en)
*
|
2011-02-02 |
2012-11-29 |
Emory University |
Antagonism of the vip signaling pathway
|
|
US20140094432A1
(en)
|
2012-10-02 |
2014-04-03 |
Cerulean Pharma Inc. |
Methods and systems for polymer precipitation and generation of particles
|
|
US9458217B2
(en)
*
|
2013-12-05 |
2016-10-04 |
Emory University |
Methods of managing graft versus host disease
|
|
US10308719B2
(en)
|
2015-01-26 |
2019-06-04 |
The University Of Chicago |
IL13Rα2 binding agents and use thereof in cancer treatment
|
|
WO2016123143A1
(en)
|
2015-01-26 |
2016-08-04 |
The University Of Chicago |
CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
|
|
TW201912173A
(zh)
|
2017-08-07 |
2019-04-01 |
美商安進公司 |
三陰性乳癌或結腸直腸癌伴隨肝轉移之治療
|
|
CN111565744A
(zh)
|
2017-09-18 |
2020-08-21 |
加利福尼亚大学董事会 |
紧密连接蛋白6抗体和治疗癌症的方法
|
|
JP2022507688A
(ja)
*
|
2018-11-15 |
2022-01-18 |
エモリー ユニバーシティー |
血管作用性小腸ペプチド（ｖｉｐ）アンタゴニストの組成物及び用途
|
|
WO2020191342A1
(en)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Claudin-6 antibodies and drug conjugates
|
|
CA3136496A1
(en)
|
2019-04-09 |
2020-10-15 |
The Board Of Trustees Of The University Of Illinois |
Drug adsorbed highly porous activated carbon for enhanced drug delivery
|
|
CA3132656A1
(en)
|
2019-04-30 |
2020-11-05 |
Instituto De Medicina Molecular Joao Lobo Antunes |
Rank pathway inhibitors in combination with cdk inhibitors
|
|
CA3140904A1
(en)
|
2019-06-24 |
2020-12-30 |
Amgen Inc. |
Inhibition of sirp-gamma for cancer treatment
|
|
CN112661739A
(zh)
*
|
2020-12-30 |
2021-04-16 |
福建省中科生物股份有限公司 |
一种萜酚类化合物及其与顺铂联用在抗肿瘤医药上的用途
|